COVID-19: a Quantitative Approach

In a piece at The Hill physician and epidemiologist Dorry Segev advocates a more quantitative approach to dealing with COVID-19:

Instead of just guessing, or assuming “one size fits all” (we saw what a disaster it caused when we assumed immunocompromised patients had the same response as everyone else), we can now test antibody levels and recommend boosters when levels fall below some threshold. We can even choose different thresholds for people of different risk profiles: If you have a higher risk of exposure to SARS-CoV-2 (or exposing others) because of your job, or if you have a higher risk of getting very sick with COVID-19 because of your comorbidity profile, you should get boosted at a higher antibody level. B if you have minimal exposure and are otherwise quite healthy, you could wait to reach a lower antibody level before boosting. This individualized approach would optimize protection while making the best use of available vaccine doses.

Antibody testing can also help us address the major controversy over natural immunity and “vaccine passports.” Many venues, including theaters and concerts and festivals, are starting to require proof of vaccination for entry. Unfortunately, this is quite a blunt instrument for determining how safe someone is to be around others, and it is becoming more and more unreliable as antibody levels from initial “full” vaccination are waning. Ideally, a space is safer if everyone in the space is immune: The risk of someone bringing the virus to the space is minimized, and the risk that the virus would impact the other immune folks in the space is also minimized.

So why have “immunity passports” devolved to “vaccine passports”? For a while, checking vaccination was much easier than somehow determining that someone had enough natural immunity to be safe: In the large clinical trials, nearly everyone mounted a strong antibody response to vaccination, so asking to see someone’s vaccine card was as close to a guarantee as we get these days that the person was immune. However, we are almost a year into vaccines, and antibody levels wane. Today, even vaccination does not necessarily mean strong immunity, and someone who had documented COVID-19 three months ago is likely more immune that someone who was vaccinated a year ago. The way to determine this is to check antibody levels: At a given antibody level, no matter how you got there (vaccines with or without boosters, natural infection with or without vaccines), it is safe for you to be around others.

It makes sense to me. However, nothing will be perfect and nothing will be risk-free. What’s the objective?

2 comments… add one
  • PD Shaw Link

    I think what is referring to is a correlate of protection, which in this case would be the antibody measurement that correlates to a defined endpoint (death, hospitalization, disease or infection). They have been working on this, but AFAIK they are still working on it. A correlate of protection for SARS-CoV-2 vaccines is urgently needed

    I don’t know whether this leads to everyone getting individualized assessments to avoid perpetual boosters because perpetual antibody testing is not an efficient public health response either. The correlate of protection for influenza is used to trigger regulatory directives to change the formula once a sample falls below the desired measurement. Correlates of protection can also be used to develop new vaccines and treatments when infection levels are too low for the type of testing used to approve the mRNA vaccines.

  • steve Link

    A lot of testing to make it work, and i am still not sure if antibodies or T cells are what you want to measure for long term immunity.

    Steve

Leave a Comment